lunedì, 4 maggio 2026

Notizie AIOM – anno XV

FDA Grants Pertuzumab Priority Review for HER2+ Early Breast Cancer

September 29, 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pertuzumab for use in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer. The sBLA ...
Leggi tutto

Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®)

Palmoplantar erythrodysesthesia (PPE) is one of the most frequent side effects during systemic treatment with pegylated liposomal doxorubicin (PLD, Caelyx®). PPE lesions show a range of symptoms, from numbness to painful erosions, and can have a major impact on the quality ...
Leggi tutto

27 Settembre 2017

26 settembre 2017 – Precisazioni su modalità inserimento dati

27 Settembre 2017

26 settembre 2017 – PANGEA X: in aumento gli italiani che si rivolgono ai canali illegali per l’acquisto di farmaci

27 Settembre 2017

25 settembre 2017 – Approvati i progetti del Bando AIFA 2016 per la ricerca indipendente

27 Settembre 2017

Lo screening può salvarti la vita!

Cittadinanzattiva lancia una campagna informativa digital sui principali social network, con hashtag #nonaspettare, di supporto al programma nazionale di screening per il cancro alla mammella, al colon retto e alla cervice uterina. Obiettivo è quello di raggiungere ...
Leggi tutto

27 Settembre 2017

27 settembre 2017 – AIFA aggiorna le tabelle dei farmaci di classe A e H

27 Settembre 2017

FDA Accepts Lenvatinib Application for Advanced HCC

September 26, 2017 - The FDA has accepted a supplemental new drug application for lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC), according to a statement from the company developing the therapy, Eisai. Under ...
Leggi tutto

27 Settembre 2017

Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25, 2017 - The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non–small cell lung cancer (NSCLC) and previously-treated locally advanced ...
Leggi tutto

27 Settembre 2017

Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study

Increasing physical activity can improve cognition in healthy and cognitively impaired adults; however, the benefits for cancer survivors are unknown. The current study examined a 12-week physical activity intervention, compared with a control condition, on objective and ...
Leggi tutto